JAZZ PHARMACEUTICALS PLC Share · IE00B4Q5ZN47 · JAZZ · A1JS1K (XNAS) Irland · Healthcare — real-time prices and quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of JAZZ PHARMACEUTICALS PLC
No Price
18.05.2026 20:00
Current Prices from JAZZ PHARMACEUTICALS PLC
| Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
|---|---|---|---|---|---|
NASDAQ |
JAZZ
|
USD
|
18.05.2026 20:00
|
229,55 USD
| 0,78 USD
+0,34 %
|
IEX |
JAZZ
|
USD
|
18.05.2026 19:59
|
229,57 USD
| 0,80 USD
+0,35 %
|
Quotrix |
JPPLCR47.DUSD
|
EUR
|
18.05.2026 05:27
|
195,65 EUR
| 5,25 EUR
+2,76 %
|
Hannover |
JPPLCR47.HANB
|
EUR
|
15.05.2026 06:03
|
193,25 EUR
| - |
Düsseldorf |
JPPLCR47.DUSB
|
EUR
|
14.05.2026 14:00
|
197,55 EUR
| - |
Hamburg |
JPPLCR47.HAMB
|
EUR
|
14.05.2026 06:05
|
198,60 EUR
| - |
Invested Funds
The following funds have invested in JAZZ PHARMACEUTICALS PLC:
Fund | Vol. in million 135,19 | Percentage (%) 7,01 % |
Fund | Vol. in million 433,94 | Percentage (%) 7,01 % |
Fund | Vol. in million 818,09 | Percentage (%) 7,01 % |
Fund | Vol. in million 334,21 | Percentage (%) 7,01 % |
Fund | Vol. in million 14.731,70 | Percentage (%) 3,84 % |
Company Profile for JAZZ PHARMACEUTICALS PLC Share
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Company Data
Name JAZZ PHARMACEUTICALS PLC
Company Jazz Pharmaceuticals plc
Symbol JAZZ
Website
https://www.jazzpharma.com
Primary Exchange
NASDAQ
NASDAQ
WKN A1JS1K
ISIN IE00B4Q5ZN47
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Renee D. Gala
Market Capitalization 14 Mrd.
Country Ireland
Currency USD
Employees 2,8 T
Address Waterloo Exchange, 4 Dublin
IPO Date 2007-06-01
Ticker Symbols
| Name | Symbol |
|---|---|
| Düsseldorf | JPPLCR47.DUSB |
| Frankfurt | J7Z.F |
| Hamburg | JPPLCR47.HAMB |
| Hannover | JPPLCR47.HANB |
| NASDAQ | JAZZ |
| Quotrix | JPPLCR47.DUSD |
More Shares
Investors who hold JAZZ PHARMACEUTICALS PLC also have the following shares in their portfolio: